EPOCH方案治疗复发耐药中高度恶性非何杰金氏淋巴瘤临床疗效

Clinical outcomes for patients with relapsed or resistant advanced non- Hodgkin's lymphoma treated by EPOCH regimen

目的观察EPOCH方案治疗复发耐药中高度恶性非何杰金氏淋巴瘤(NHL)的疗效和不良反应。方法2002年12月至2004年12月我院收治复发耐药NHL17例,用VP-1650mg/m2/d、ADM或THP10mg/m2/d、VCR0.4mg/m2/d持续静脉滴注第1～4天,CTX750mg/m2/d静注第5天,强的松60mg/m2/d口服第1～5天,21天为一个疗程。结果本组17例均可评价疗效和不良反应,总有效率58.8%,完全缓解率(CR)23.5%,部分缓解率(PR)35.3%。主要不良反应为骨髓抑制,其他不良反应少见。结论EPOCH方案是复发耐药中高度恶性NHL经济有效的治疗方案,毒性可耐受。

Objective To evaluate the efficacy and toxicity of EPOCH regimen in patients with relapsed or refractory non- Hodgkin's lymphoma(NHL). Methods All 17 patients were treated with EPOCH regimen, VP-16 50mg/m^2/d、ADM or THP10mg/m^2/d、VCR0.4mg/m^2/d , CIV on days 1~4,CTX750mg/m^2/d iv on day 5,Pred 60mg/m^2/d on days 1~5, every 21 days. Results All the 17 patients were assessable. The overall response rate was 58.8%, CR 23.5%, PR 35.3% .Major toxicity was myelosuppression. Other toxicities were mild. Concusion EPOCH is effective and well tolerant for the patients with relapsed or refractory non- Hodgkin's lymphoma.